This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Follow HCPLive's coverage of the full-day FDA committee meeting regarding Lykos Therapeutics' application for MDMA-assisted therapy as a novel treatment for patients with PTSD.
Embargoed until 4 a.m. CT/5 a.m. ET Tuesday, June 4, 2024 DALLAS, June 4, 2024 — Driven by an older, more diverse population, along with a significant increase in risk factors including high blood pressure and obesity, total costs related to.
Driven by an older, more diverse population, along with a significant increase in risk factors including high blood pressure and obesity, total costs related to cardiovascular disease (CVD) conditions are likely to triple by 2050, according to recent projections. At least 6 in 10 U.S. adults (61%), more than 184 million people, are expected to have some type of CVD within the next 30 years, reflecting a disease prevalence that will have a $1.8 trillion price tag in direct and indirect costs.
A majority of adults in the U.S. — around 61% — are likely to be diagnosed with a form of cardiovascular disease by 2050, according to new American Heart Association data. The increased burden will cost the U.S. health system $1.8 trillion in the time frame.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
DALLAS, date, 2024 — Significant barriers prevent or slow treatment for many patients with stroke, including long travel times to stroke center hospitals and the lack of availability of stroke specialists who can evaluate the patient and determine if.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. Image courtesy: Caristo Diagnostics christine.book Tue, 06/04/2024 - 10:00 June 4, 2024 — Caristo Diagnostics Limited , a global provider of cardiovascular disease diagnostics and risk prediction, has announced the results of a landmark clinical stud
The DanShock trial (NCT01633502) assessed the efficacy of the Impella CP ventricular assist device in reducing mortality following myocardial infarction (MI). The Impella CP is a catheter-based axial flow pump that directly channels blood from the left ventricle into the circulation, delivering 3.5L/min (approximately 75% of normal cardiac output). Investigators randomized 360 patients to receive either a microaxial flow pump plus standard of care (SOC) (n=179) or SOC alone (n=176).
The DanShock trial (NCT01633502) assessed the efficacy of the Impella CP ventricular assist device in reducing mortality following myocardial infarction (MI). The Impella CP is a catheter-based axial flow pump that directly channels blood from the left ventricle into the circulation, delivering 3.5L/min (approximately 75% of normal cardiac output). Investigators randomized 360 patients to receive either a microaxial flow pump plus standard of care (SOC) (n=179) or SOC alone (n=176).
Stroke recovery is a challenging process that extends for months after hospital discharge. Issues like cognitive impairment and social determinants of health (SDOH) hurdles often go unrecognized until patients are home. To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period.
Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.
June 4, 2024 — The countdown has begun ahead of the American Society of Echocardiography 35th Annual ASE Scientific Sessions, June 14-26, at the Oregon Convention Center in Portland, OR. This year’s program, “Global Echocardiography: Innovations in Diagnosis and Beyond,” is described as an educational experience gathering global experts and enthusiasts in echocardiography, hosted by the largest global organization for cardiovascular ultrasound imaging serving physicians, sonographers, nurses, a
milla1cf Tue, 06/04/2024 - 20:51 June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and the Southwest — to undergo a non-surgical, catheter-based procedure with a new type of stroke-prevention stent that eliminates blockages in neck arteries that could potentially cause a deadly stoke by depriving the brain of oxygen.
(MedPage Today) -- FDA reviewers questioned the cardiac safety of midomafetamine (MDMA), among other concerns raised ahead of an advisory committee meeting on a potential drug indication for post-traumatic stress disorder. Annual healthcare costs.
Here is a look at the Top 10 pieces of content viewers were reading during the month of May. 1. American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.
milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product. Five Medicare Administrative Contractors (MACs), CGS, NGS, Noridian, Palmetto GBA, and WPS, released draft Local Coverage Determinations (LCD) for Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaqu
The United Nations Sustainable Development Goals for 2030 include a strong focus on health, wherein it is stated “…to extend life expectancy for all, we must achieve universal health coverage and access to quality health care. No one must be left behind.” While some progress has been made, rheumatic heart disease (RHD) provides a tragic example of how, in some ways, we are far from this idealistic goal.
Circulation, Ahead of Print. BACKGROUND:Cardiovascular disease and stroke are common and costly, and their prevalence is rising. Forecasts on the prevalence of risk factors and clinical events are crucial.METHODS:Using the 2015 to March 2020 National Health and Nutrition Examination Survey and 2015 to 2019 Medical Expenditure Panel Survey, we estimated trends in prevalence for cardiovascular risk factors based on adverse levels of Life’s Essential 8 and clinical cardiovascular disease and stroke
Energy drinks potentially can trigger life-threatening cardiac arrhythmias. It has been postulated that the highly stimulating and unregulated ingredients alter heart rate, blood pressure, cardiac contractility, and cardiac repolarization in a potentially proarrhythmic manner.
Circulation, Ahead of Print. BACKGROUND:Quantifying the economic burden of cardiovascular disease and stroke over the coming decades may inform policy, health system, and community-level interventions for prevention and treatment.METHODS:We used nationally representative health, economic, and demographic data to project health care costs attributable to key cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia) and conditions (coronary heart disease, stroke, heart failure, at
In patients with a history of stroke or those at high risk of developing stroke, a continuous rhythm monitoring strategy using implantable loop recorders (ILR) is often performed to screen for atrial fibrillation (AF).
This cohort study evaluates which emergency medical services practices are associated with favorable neurological survival for out-of-hospital cardiac arrest using data from the Cardiac Arrest Registry to Enhance Survival.
Neijenhuis et al. and Fusco et al. addressed the safety, tolerability, and outcomes of patients with adult congenital heart disease (ACHD) treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i).
In this interview, Michael D. Shapiro, DO, FACC and Roger S. Blumenthal MD, FACC explore CAC scoring and the role of calcium detection in tailoring patient care, personalized risk assessment, and the prevention of future cardiac events.
DALLAS, 4 de junio de 2024 — Significativas barreras impiden o retrasan el tratamiento para muchos pacientes que han sufrido un derrame cerebral, incluidos los largos tiempos de viaje a hospitales especializados y la falta de disponibilidad de.
Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.
The goal of the Dual vs. Single DCCV trial was to determine the efficacy and safety of dual direct-current cardioversion (DCCV) compared with single DCCV in patients with obesity and atrial fibrillation (AF) undergoing elective electrical cardioversion.
This review of May 2024 covered several notable topics in the pulmonary health field, including research into vaping, lung abnormalities, and treatment of COPD.
What is the forecasted cost offset that could be realized with optimal implementation of sodium glucose co-transporter 2 inhibitor (SGLT2i) therapy for patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≤40% and >40%?
Prohibida su publicación hasta las 4 a. m., CT/5 a. m., ET del martes, 4 de junio de 2024 DALLAS, 4 de junio de 2024 — Impulsados por una población mayor y más diversa, junto con un aumento significativo de los factores de riesgo, como la presión.
Aberrant left coronary artery from pulmonary artery (ALCAPA) is a very rare congenital heart defect. Its coexistence with patent ductus arteriosus (PDA) is extremely rare. The high pr.
The month of May 2024 featured several notable studies in the field of dermatology, concerning topics such as a potential eczema flare vaccine, mobile versus in-person health, and skin cancer risk.
Pre-operative coronary angiography and concomitant, planned coronary artery bypass are infrequently performed with type A aortic dissection repair. We present a case in which pre-operative coronary computed to.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content